|Other names||Desmethylapalutamide; Norapalutamide|
|Drug class||Nonsteroidal antiandrogen|
|Chemical and physical data|
|Molar mass||463.41 g·mol−1|
|3D model (JSmol)|
N-Desmethylapalutamide is a nonsteroidal antiandrogen (NSAA) and the major active metabolite of apalutamide, an NSAA which is used as a hormonal antineoplastic agent in the treatment of metastatic prostate cancer. It has similar activity to that of apalutamide and, with apalutamide therapy, circulates at similar concentrations to those of apalutamide at steady state.[failed verification] N-Desmethylapalutamide is formed from apalutamide in the liver by the cytochrome P450 enzymes CYP2C8 and CYP3A4.
- "ERLEADATM (apalutamide) tablets, for oral use" (PDF). Janssen Biotech, Inc. U.S. Food and Drug Administration.
- Pérez-Ruixo C, Pérez-Blanco JS, Chien C, Yu M, Ouellet D, Pérez-Ruixo JJ, Ackaert O (February 2020). "Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects". Clinical Pharmacokinetics. 59 (2): 229–244. doi:10.1007/s40262-019-00808-7. PMID 31432469. S2CID 201065140.